{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"6.62","value":"10.4"},{"groupId":"OG001","spread":"4.31","value":"13.4"},{"comment":"Single participant analyzed","groupId":"OG002","spread":"NA","value":"6.33"},{"groupId":"OG003","spread":"8.67","value":"16.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"}],"units":"Participants"}],"title":"Cmax (ng/mL) Day 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.2","value":"10.6"},{"groupId":"OG001","spread":"2.58","value":"11.3"},{"comment":"Single participant analyzed","groupId":"OG002","spread":"NA","value":"5.61"},{"groupId":"OG003","spread":"4.05","value":"15.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"title":"Cmax (ng/mL) Day 56"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"description":"Pharmacokinetics (PK) of octreotide after administrations of CAM2029 was determined for the dosing period Day 0 to Day 84 ; Cmax (ng/mL).\n\nCmax (ng/mL): Maximum observed plasma concentration over CAM2029 20 mg q4w and CAM2029 10 mg q2w dosing intervals (ng/mL)","dispersionType":"Standard Deviation","groups":[{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks\n\noctreotide FluidCrystal® injection depot","id":"OG000","title":"CAM2029 10 mg q2w (Acromegaly)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly\n\noctreotide FluidCrystal® injection depot","id":"OG001","title":"CAM2029 20 mg q4w (Acromegaly)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 10 mg, subcutaneous injection every two weeks\n\noctreotide FluidCrystal® injection depot","id":"OG002","title":"CAM2029 10 mg q2w (NET)"},{"description":"CAM2029 (octreotide FluidCrystal® injection depot) 20 mg, subcutaneous injection once monthly\n\noctreotide FluidCrystal® injection depot","id":"OG003","title":"CAM2029 20 mg q4w (NET)"}],"paramType":"MEAN","populationDescription":"Pharmacokinetic population, two patients excluded from the CAM2029 20mg Acromegaly due to incorrect dose.","reportingStatus":"POSTED","timeFrame":"(Day 0) to Day 84 (PK analysis:CAM2029 sampling time points: CAM2029 10mg q2w; 0, 2hours, 24hours, 48hours, 7days and 14days CAM2029 20mg q4w; 0, 2hours, 24hours, 48hours, 7days, 21days and 28days)","title":"Pharmacokinetic (PK) Profile of Octreotide After Each Injection of CAM2029 as Compared With Baseline PK for Sandostatin® Long-acting Release (LAR®) Cmax.","type":"PRIMARY","unitOfMeasure":"ng/mL"}